Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|August 28, 2015
Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibitionLindsay Nicholson, Caroline A Evans, Elizabeth Matheson, et al.
BMJ Open|March 20, 2021
Investigating inequities in cardiovascular care and outcomes for Queensland Aboriginal and Torres Strait Islander people: protocol for a hospital-based retrospective cohort data linkage projectTherese Kearns, Abbey Diaz, Lisa J Whop, et al.
Cell Reports|August 4, 2022
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar developmentDaniel Williamson, Edward C Schwalbe, Debbie Hicks, et al.
The Lancet. Oncology|May 27, 2017
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort studyEdward C Schwalbe, Janet C Lindsey, Sirintra Nakjang, et al.
Acta Neuropathologica|December 6, 2011
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastomaSarra L Ryan, Ed C Schwalbe, Michael Cole, et al.
Acta Neuropathologica Communications|November 21, 2013
Identification of a neuronal transcription factor network involved in medulloblastoma developmentMaria Lastowska, Hani Al-Afghani, Haya H Al-Balool, et al.
Cell Reports|October 27, 2016
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid TumorsJocelyn P Wong, Jason R Todd, Martina A Finetti, et al.
Nature Communications|August 30, 2020
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunityYura Grabovska, Alan Mackay, Patricia O'Hare, et al.
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Acta Neuropathologica|April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratificationJack Goddard, Jemma Castle, Emily Southworth, et al.
Pageof 8